Texas Oncology-The Woodlands, Gynecologic Oncology
Welcome,         Profile    Billing    Logout  
 9 Trials 
24 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee, Christine H
DPPOS, NCT00038727: Diabetes Prevention Program Outcomes Study

Active, not recruiting
3
2779
US
DPPOS Group Lifestyle, Metformin, Glucophage, DPPOS Boost Lifestyle, Intensive Lifestyle Group Session, Intensive lifestyle session (ILS)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Aging (NIA), National Institute on Minority Health and Health Disparities (NIMHD), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), National Eye Institute (NEI), National Center for Research Resources (NCRR), Office of Research on Women's Health (ORWH), Centers for Disease Control and Prevention, American Diabetes Association, Indian Health Service, General Clinical Research Program, US Department of Veterans Affairs
Diabetes Mellitus, Cancer, CVD
10/24
01/25
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
REFRaME-O1, NCT05870748: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Recruiting
2/3
600
Canada, US, RoW
Luveltamab tazevibulin, STRO-002, Luvelta, Pegfilgrastim, Neulasta, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Sutro Biopharma, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
08/27
02/28
ZN-c3-004, NCT04814108: A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Recruiting
2
76
Canada, US, RoW
ZN-c3, azenosertib, KP-2638
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Uterine Serous Carcinoma
11/24
05/25
PROFECTA-II, NCT04374630: Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Completed
2
150
US, RoW
Paclitaxel, Afuresertib, LAE002
Laekna Limited
Platinum-resistant Ovarian Cancer
07/23
06/24
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRĪ± +ve PROC
Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Completed
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
AbbVie
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
NCT04202211: FMT for Remission of Active Ulcerative Colitis in Adults

Withdrawn
2
145
Canada
FMT oral, FMT enema, Placebo oral, Placebo enema
University of British Columbia, Crohn's and Colitis Canada
Ulcerative Colitis, Inflammatory Bowel Diseases
12/24
12/28
PRESERVE-004, NCT05446298: ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Active, not recruiting
2
58
US
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, MK3475, Keytruda
OncoC4, Inc., Merck Sharp & Dohme LLC, GOG Foundation
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
06/25
06/26
NCT03806803: Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection

Completed
2
138
Canada
Lyophilized fecal microbiota transplant, Lyophilized sterile fecal filtrate
University of Alberta, University of British Columbia, University of Calgary, McGill University
Clostridia Difficile Colitis, Clostridium Difficile Diarrhea
03/24
03/24
CASTLE, NCT05613946: Contrast-Enhanced Ultrasound and Shear Wave Elastography for the Treatment of Lymphedema

Completed
1
26
US
Lumason, sulfur hexafluoride lipid-type A microspheres, Optison, perflutren protein-type A microspheres, Definity, perflutren lipid microsphere
Mayo Clinic
Lymphedema Arm
06/24
06/24
AMPS, NCT04213846: Alcohol & Mobile Phone Study to Reduce High-risk Alcohol Use and Consequences

Completed
N/A
408
US
Experimental: Mobile Alcohol Expectancy Intervention
University of Washington, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol; Use, Problem
04/22
04/22
NCT06441188: Sonography of the Nipple Areolar Complex

Active, not recruiting
N/A
20
US
Thin layer conventional ultrasound coupling gel, Thick layer of conventional ultrasound coupling gel, Thin conventional ultrasound coupling gel pad, Thick conventional ultrasound coupling gel pad
Mayo Clinic
Healthy
10/24
03/25
NCT05547347: Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients with Locally Advanced Breast Cancer

Enrolling by invitation
N/A
15
US
Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Mammogram, Ultrasound, Ultrasound-Guided Biopsy, Ultrasound Guided Biopsy, Twinkle marker
Mayo Clinic, National Cancer Institute (NCI)
Anatomic Stage III Breast Cancer AJCC V8, Locally Advanced Breast Carcinoma, Resectable Breast Carcinoma
12/25
12/25
NCT04692818: 3D Ultrasound Breast Imaging

Recruiting
N/A
125
US
GE Logiq E10 clinical ultrasound scanner, Verasonics research scanner
Mayo Clinic, United States Department of Defense
Breast Tumor
12/25
12/26
FETO, NCT05461222: Fetal Endoscopic Tracheal Occlusion () for Severe Congenital Diaphragmatic Hernia

Recruiting
N/A
15
US
Balt "Goldballoon"
Yair Blumenfeld
Congenital Diaphragmatic Hernia
08/25
08/27
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29
Allen, Kathryn
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
OVATION 2, NCT03393884: Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer

Checkmark Presentation of OVATION 2 data in advanced ovarian cancer
Mar 2021 - Mar 2021: Presentation of OVATION 2 data in advanced ovarian cancer
Active, not recruiting
1/2
130
Canada, US
IMNN-001, Carboplatin, Paclitaxel
Imunon
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
07/24
11/25
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29
Anderson, Josie
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29
Salame, Ghadir
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29
Watkins, Kelli
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29

Download Options